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Background. Lysine-specific demethylase 1 (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9,
exhibits diverse transcriptional activities by mediating chromatin reconfiguration. The telomerase reverse transcriptase
(hTERT) gene, encoding an essential component for telomerase activity that is involved in cellular immortalization and
transformation, is silent in most normal human cells while activated in up to 90% of human cancers. It remains to be defined
how exactly the transcriptional activation of the hTERT gene occurs during the oncogenic process. Methodology/Principal
Findings. In the present study, we determined the effect of LSD1 on hTERT transcription. In normal human fibroblasts with a
tight hTERT repression, a pharmacological inhibition of LSD1 led to a weak hTERT expression, and a robust induction of hTERT
mRNA was observed when LSD1 and histone deacetylases (HDACs) were both inhibited. Small interference RNA-mediated
depletion of both LSD1 and CoREST, a co-repressor in HDAC-containing complexes, synergistically activated hTERT
transcription. In cancer cells, inhibition of LSD1 activity or knocking-down of its expression led to significant increases in levels
of hTERT mRNA and telomerase activity. Chromatin immunoprecipitation assay showed that LSD1 occupied the hTERT
proximal promoter, and its depletion resulted in elevated di-methylation of histone H3-K4 accompanied by increased H3
acetylation locally in cancer cells. Moreover, during the differentiation of leukemic HL60 cells, the decreased hTERT expression
was accompanied by the LSD1 recruitment to the hTERT promoter. Conclusions/Significance. LSD1 represses hTERT
transcription via demethylating H3-K4 in normal and cancerous cells, and together with HDACs, participates in the
establishment of a stable repression state of the hTERT gene in normal or differentiated malignant cells. The findings
contribute to better understandings of hTERT/telomerase regulation, which may be implicated in the development of
therapeutic strategies for telomerase dysregulation-associated human diseases including cancers.
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INTRODUCTION
The post-translational modification of nucleosomal histones,
including acetylation, phosphorylation, methylation, ubiquitina-
tion and sumoylation, plays a key role in the regulation of gene
transcription through remodelling chromatin structure [1]. Among
all above modifications, regulated methylation of six known lysine
(K) residues within the tails of histone H3 (H3-K4, H3-K9, H3-
K27, H3-K36 and H3-K79) and H4 (H4-K20) is unique as mono-
(M1), di- (M2) and tri- (M3) three modification states can be
generated [2,3]. These different states, together with the identity of
the modified lysine residues, result in diverse consequences on
transcriptional activities. Methylation of H3-K4, H3-K36 and H3-
79 is predominantly associated with transcriptionally active genes,
whereas methylation of H3-K9, H3-K27 and H4-K20 marks silent
genes or heterochromatin [1–3].
It is well known that histone acetylation and phosphorylation
are dynamic and reversible, while histone methylation has long
been thought as a static modification [1–3]. However, the recent
discovery of multiple histone demethylases (HDMs) has totally
changed this dogma, and thus the dynamic histone H3
methylation–mediated transcriptional regulation has emerged as
a subject of intense investigations [2–5]. Lysine-specific demethy-
lase 1 (LSD1), the first identified HDM [6], has attracted a great
deal of interest because of its broad functional activities in
transcriptional programs [7–15]. By interacting with diverse co-
factors and catalyzing demethylation of mono- and di-methylated
H3-K4 or K9, LSD1 is capable of either repressing or activating
the target genes. For instance, when recruited to the target
promoters by the androgen receptor, LSD1 removed the
repressive H3-K9(M2) mark, thereby driving the androgen target
activation [7,11–13]. On the other hand, LSD1 specifically
demethylates H3-K4(M1) and (M2) that in turn leads to gene
repression by maintaining a unmethylated H3-K4 status on its
target promoters [6,8,13,16,17]. By eliciting such dual effects,
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differentiation and proliferation, stem and cancer cell biology.
Telomerase, a RNA-dependent DNA polymerase silent in most
normal human somatic cells, is frequently activated during the
oncogenic process [18,19]. The compelling evidence suggests that
activation of telomerase is essential for cellular immortalization and
malignant transformation [18,19]. Moreover, telomerase and/or its
components have also been implicated in the regulation of stem cell
mobilization and proliferation [20,21]. It has been established that
the stable repression of the telomerase catalytic subunit, encoded by
the telomerase reverse transcriptase (hTERT) gene, is a predominant event
resulting in the lack of telomerase activity in most normal cells [22–
26]. Therefore, in order to acquire telomerase activity, it is necessary
to erase negative regulators suppressing hTERT transcription.
However, it remains incompletely understood how the repression or
activation of the hTERT gene in normal and cancerous cells is
achieved, despite great efforts in elucidating the underlying
mechanisms during the past years.
Recent studies have started to uncover a close association
between histone modifications including methylation and tran-
scriptional activity of the hTERT gene in human cells [27–35].
Lack of histone H3-K4 methylation generally marks the repressive
hTERT transcription in telomerase-deficient cells while the over-
expression of SMYD3, a histone methyltransferase (HMT) that
specifically di- and tri-methylates histone H3-K4, leads to the
induction of hTERT mRNA expression via enhancing methylated
H3-K4 at the hTERT proximal promoter region [34,35]. It has
been shown that the transcription factor c-MYC, a key activator of
the hTERT gene [36,37], is capable of binding to its target
promoters only when the H3-K4 is methylated within appropriate
regions of target promoters [38]. Conceivably, histone H3-K4
demethylation at the hTERT promoter may be required to lock
the chromatin in a closed state in telomerase-deficient cells.
However, it remains unknown which HDMs are associated with
the hTERT promoter and responsible for maintaining H3-K4
demethylation locally. In the present study, we sought to address
this issue by determining the potential role for LSD1 in controlling
hTERT transcription.
RESULTS
Tranylcypromine treatment or depletion of LSD1
expression induces hTERT mRNA expression in
MRC5 fibroblasts
The amino oxidase inhibitor tranylcypromine has been identified
to potently suppress the enzymatic activity of LSD1 [17].
Therefore, to elucidate a potential role for LSD1 in the
transcriptional regulation of the hTERT gene, we first incubated
normal human MRC5 fibroblasts exhibiting a stable hTERT
repression in the presence of tranylcypromine. As shown in
Fig. 1A, hTERT transcripts were not observed in control MRC5
cells while tranylcypromine treatment induced a weak but
detectable expression of hTERT mRNA. To rule out possible
LSD1-independent, non-specific effects of tranylcypromine, we
Figure 1. The effect of LSD1 inhibition on the hTERT mRNA
expression or gene transcription in human normal fibroblast MRC5
cells. (A) The induction and synergistic up-regulation of hTERT mRNA
expression in MRC5 cells by the LSD1 inhibitor tranylcypromine alone
and its combined treatment with the histone deacetylase (HDAC)
inhibitor TSA, respectively. The cells were incubated with either
tranylcypromine at 25.0 mM or TSA 0.1 mM, or both of them overnight
and then harvested for hTERT mRNA analyses using RT-PCR. Trans:
tranylcypromine. (B) The synergistic effect of LSD1 and CoREST
depletion on the induction of hTERT mRNA in MRC5 cells. The
knocking-down of LSD1 and CoREST expression was performed using
the specific siRNA targeting LSD1 and CoREST. Arrow: primer dimmers.
(C) The demonstration of efficient down-regulation of the target genes
in siRNA-transfected cells. Lane 1: Control siRNA; lane 2: LSD1 (Upper)
and CoREST siRNAs (Lower), respectively; and lane 3: LSD1+CoREST
siRNAs. Note the results in (B) and (C) were from the same set of cDNA,
and therefore, b2 –M was only shown in (B). (D) The up-regulation of
the hTERT promoter activity by tranylcypromine. The p181 reporter
r
construct that harbors the hTERT proximal promoter sequence was
transfected into MRC5 cells in the absence or presence of tranylcypro-
mine, and then analysed for luciferase activity 48 hours later. Variation
in transfection efficiency was normalized by the TK-driven Renilla
luciferase activity. Columns: Relative luciferase activity arbitrarily
expressed as the ratio of p181/TK; Bars: SD.
doi:10.1371/journal.pone.0001446.g001
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siRNA. siRNA treatment of MRC5 cells resulted in silencing of
LSD1 expression, and consistent with the finding described above,
hTERT mRNA was induced in these LSD1-depleted cells
(Fig. 1B). Taken together, both pharmacological inhibition of
LSD1 activity and depletion of its expression are capable of de-
repressing the hTERT transcription in normal human fibroblasts,
although the effect was not robust.
The simultaneous inhibition of both LSD1 and
HDACs is required for the optimal induction of
hTERT mRNA expression in MRC5 cells
It has been previously shown that the inhibition of HDAC activity
by TSA activates hTERT transcription in human fibroblasts and
other cell types [27,28,31–33,39]. Moreover, an intimate interplay
between LSD1 and HDACs has been observed [40]. We thus
sought to probe whether a synergistic induction of hTERT
expression could be achieved by inhibiting both LSD1 and HDAC
activities. For this purpose, MRC5 cells were exposed to either
tranylcypromine or TSA alone, or tranylcypromine plus TSA. A
weak expression of hTERT mRNA was observed in cells treated
with tranylcypromine at 25 mM or TSA at 0.1 mM, whereas the
cell exposure to both tranylcypromine and TSA led to a robust
increase in hTERT transcripts (Fig. 1A). The data suggest that
LSD1 and HDACs cooperate to maintain a repressive state of the
hTERT transcription in normal human MRC5 cells.
Itisknown thatLSD1interacts with CoREST,a co-repressorthat
exists in the HDAC-containing complex [8,16]. To corroborate the
specific effect of tranylcypromine and TSA, we thus depleted both
LSD1 and CoREST expression in MRC5 cells using a siRNA
approach. The efficient knocking-down of these transcripts was
verifiedwith useof RT-PCR(Fig. 1C). The transfectionofLSD1 but
not CoREST siRNA into MRC5 cells induced minimal amounts of
hTERT mRNA whereas the depletion of both of them synergisti-
cally activated hTERT transcription (Fig. 1B), which was in good
accordance with the results achieved in MRC5 cells incubated with
both tranylcypromine and TSA.
The hTERT promoter is activated in MRC5 cells in the
presence of tranylcypromine
Next we sought to examine the effect of tranylcypromine on the
hTERT promoter activity. p181, a reporter construct with an
insert of the core hTERT promoter sequence [37], was transfected
into MRC5 cells and luciferase activity driven by the hTERT core
promoter was assessed 48 hours post-transfection in the presence
or absence of tranylcypromine. As expected, the p181 activity in
untreated MRC5 cells was very low, consistent with earlier
observations. The exposure of the cells to tranylcypromine
substantially increased the hTERT promoter activity in a dose-
dependent manner (Control vs tranylcypromine treatment at 10
and 100 mM, p,0.05, paired Wilcoxon two sample test) (Fig. 1D).
Tranylcypromine up-regulates hTERT expression
and telomerase activity concomitant with elevated
H3-K4(M2) and H3 acetylation at the hTERT proximal
promoter in cancer cells
Having demonstrated an inhibitory role for LSD1 in the hTERT
transcription in human normal fibroblasts, we wanted to further
clarify its regulatory effect on hTERT expression in different
cancer cells. The cervical cancer lines HeLa, SiHa and SW756,
and a lung cancer line A549 cells were incubated with different
concentrations of tranylcypromine overnight and were then
analyzed for changes in hTERT mRNA and telomerase activity.
The results documented in Fig. 2A showed a significant up-
Figure 2. The tranylcypromine-induced up-regulation of hTERT
mRNA expression and telomerase activity accompanied by increase
in H3-K4(M2) and H3 acetylation at the hTERT proximal promoter
region in human cancer cells. (A) The dose-dependent up-regulation
of hTERT mRNA expression in A549, HeLa, SiHa and SW756 cells treated
with tranylcypromine. (B) Telomerase activity in the same sets of cells
treated with tranylcypromine (Trans) at 100 mM (for A549, HeLa and
SW756) or 50 mM (for SiHa) as in (A). Telomerase activity was assessed
using a telomerase PCR ELISA kit and arbitrarily expressed as
absorbance (OD450–OD690). Columns: Relative telomerase activity;
Bars: SD. (C) The western blot analysis of global histone H3 acetylation,
H3-K4, and H3-K9 mono-, di- and tri-methylation in HeLa and SiHa cells
treated with tranylcypromine (Trans). Pansus staining was shown for
equal histone protein loads. (D) The increased histone H3-K4(M2) and
H3 acetylation at the hTERT proximal promoter in tranylcypromine-
treated HeLa and SiHa cells. Representative ChIP results were shown.
doi:10.1371/journal.pone.0001446.g002
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treated cells although the sensitivity varied from cell line to cell
line. HeLa cells were most sensitive to tranylcypromine treatment
and the concentration at 10 mM induced optimal increases in
hTERT mRNA. Consistently, an increase in telomerase activity
was observed in the same sets of A549, SiHa and SW756 cells as
well (Fig. 2B). HeLa cells treated with 100 mM tranylcypromine
exhibited slight enhancement in telomerase activity, in accordance
with hTERT mRNA results.
Given tranylcypromine’s inhibitory effect on LSD1 activity [17],
we next asked whether potential alterations in histone H3
methylation occurred in cells treated with tranylcypromine. We
first recorded a change in global histone H3 methylation and
acetylation profile in control and treated cells, but failed to find a
significant difference in total methylated H3-K4 and K9 or H3
acetylation (Fig. 2C). Chromatin immunoprecipitation (ChIP)
assays were then applied to determine histone H3 modifications at
the hTERT promoter region by using the PCR primers spanning
the proximal promoter regions (between –296 and –22 relative to
ATG). The treatment of HeLa cells with the LSD1 inhibitor led to
substantial enrichments in H3-K4(M2) at the hTERT core
promoter region (Fig. 2D). Similar alterations were observed in
SiHa cells following tranylcypromine treatment: H3-K4(M2) at
the hTERT promoter was increasingly enriched. Furthermore,
highly increased histone H3 acetylation at the hTERT promoter
region was found in both HeLa and SiHa cells in the presence of
tranylcypromine (Fig. 2D). In contrast, no significant H3-K9
methylation(M2) was detected at the hTERT proximal promoter
(Fig. 2D). These data indicate that LSD1 specifically demethylates
H3-K4 rather than K9 associated with the hTERT proximal
promoter, consistent with its inhibitory effect on the hTERT
transcription. Additionally, we found that the altered H3-K4
modification was limited to the core promoter region and did not
extend to the promoter nucleosomes further upstream (.2700
and beyond; data not shown).
Depleting LSD1 expression induces higher levels of
hTERT mRNA and telomerase activity via inhibiting
H3-K4 demethylation at the hTERT proximal
promoter in cervical cancer cells
To obtain independent evidence for the inhibitory effect of LSD1 on
hTERT transcription and telomerase activity, LSD1 expression was
further knocked-down in HeLa and SiHa cells again using a siRNA
strategy. As shown in Fig. 3A, LSD1 could be efficiently depleted in
HeLa and SiHa cells. The up-regulation of hTERT mRNA and
telomerase activity was observed in both cells, consistent with those
documented in tranylcypromine-treated cells (Fig. 3A and B).
The depletion of LSD1 in HeLa and SiHa cells did not lead to
global changes in the histone H3 methylation and acetylation
profile (Fig. 3C). We then performed ChIP analyses to define
potential alterations in H3 methylation associated with the
hTERT proximal promoter in LSD1-depleted cells. The presence
of LSD1 on the hTERT promoter was readily observed in the
control cells while it became undetectable following LSD1-specific
siRNA treatment (Fig. 3D). The depletion of LSD1 expression was
accompanied by significant increases in H3-K4(M2) and histone
H3 acetylation at the hTERT promoter in both HeLa and SiHa
cells (Fig. 3D). There were no detectable histone H3-K9(M2) at
the hTERT promoter region in either control or LSD1-depleted
cells (Fig. 3D). These results provide evidence that LSD1 targets
the hTERT gene and represses hTERT transcription via
specifically demethylating histone H3-K4 (M2) at the hTERT
proximal promoter in cervical cancer cell lines.
The recruitment of LSD1 to the hTERT promoter
accompanied by a loss of H3-K4(M2) and down-
regulation of hTERT expression occur concomitantly
during the terminal differentiation of leukemic HL60
cells
It has been well clarified that HL60 leukemic cells, when induced to
undergo terminal differentiation, exhibit a stable repression of
hTERT transcription [39,41–45]. To explore whether LSD1 is
involved in the establishment of such a repressive state of the hTERT
gene in the differentiated HL60 cells, we treated the cells with
DMSO, a differentiation inducer, and then analysed binding of
LSD1 to the hTERT proximal promoter. As expected, the DMSO
exposure of HL60 cells triggered complete cessation of hTERT
transcription within 48 hours (Fig. 4A). The ChIP results showed
that LSD1 recruitment to the hTERT promoter did not occur in
undifferentiated cells while it was readily observed in differentiated
cells treated with DMSO for 48 hours, concomitant with the loss of
H3-K4(M2) at the hTERT proximal promoter (Fig. 4B).
DISCUSSION
The methylated histone H3-K4 and K9 mark gene activation and
repression, respectively [1–3]. LSD1, the first identified histone
demethylase [6], has been shown to either repress a cohort of
target genes through demethylation of H3-K4(M2) or activate
other targets via removing the repressive mark H3-K9(M2),
dependent on its interaction with different partners [6–8,12,17]. In
the present study, we provide evidence that LSD1 is required for
transcriptional repression of the hTERT gene in both normal and
cancerous human cell lines.
Previous observations showed that the entire hTERT gene was
embedded in a highly condensed chromatin in human normal
fibroblasts with a tight repression of hTERT transcription [29,30].
When treated with a HDAC inhibitor, the local chromatin
became open due to the increased histone acetylation, which thus
allowed the transcriptional activation of the hTERT gene [22–26].
These data indicate an important role for HDAC-mediated
histone deacetylation in repressing hTERT expression in telome-
rase-deficient cells. It is evident from the present investigation that
LSD1 is similarly required for the establishment of repressive
hTERT chromatin in normal fibroblasts. The activation of an
optimal hTERT transcription can be achieved only when LSD1
and HDACs are both inhibited. Taken together, LSD1-mediated
H3-K4 demethylation and HDAC-mediated histone deacetylation
cooperate to establish a repressive transcriptional environment at
the hTERT promoter region in human normal fibroblasts.
Moreover, the recruitment of LSD1 to the hTERT promoter
observed in differentiated HL60 cells provides independent
evidence for its participation in the stable repression of the
hTERT gene. It is currently unclear whether other histone
demethylases are involved in the H3-K4 demethylation at the
hTERT chromatin. This issue is now being addressed in our
laboratory.
Intriguingly, the temporal patterns of expression of specific
components of the LSD1 complex during the mammalian
development cause a switch of LSD1 function from repression to
activation, or reverse [13]. Therefore, we compared the
transcriptional effect of LSD1 on the hTERT gene between cancer
and normal cells. All the tested cancer cells including HeLa, SiHa,
SW756 and A549 expressed hTERT mRNA and telomerase
activity, but the pharmacological inhibition of LSD1 activity or
depletion of its expression was capable of further up-regulating
hTERT mRNA and telomerase activity levels, which clearly
hTERT Repression by LSD1
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transcription in both normal and cancer cells. More importantly,
the ChIP result demonstrated the LSD1 occupancy on the
hTERT proximal promoter. Consistent with its functional activity,
inhibition of LSD1 led to increased histone H3-K4 (M2) at the
hTERT promoter region. In contrast, there were no detectable
changes in H3-K9 methylation locally. It seems that LSD1 only
targets H3-K4 for its demethylation at the hTERT promoter.
Moreover, the LSD1-mediated H3-K4 demethylation was con-
fined to the core promoter region without a further extension to
upstream nucleosomes based on our unpublished data.
H3-K4 methylation alters the chromatin folding, leading to
increased accessibility of DNA to proteins that mediate transcrip-
tion [1–3]. It has been shown that the methylated H3-K4 is one of
the prerequisites for the E-box binding by c-MYC on MYC target
promoters [34,38]. Given the fact that hTERT gene is a direct
target of c-MYC [36,37], the LSD1-mediated H3-K4 demethyl-
ation might prevent the c-MYC binding to the hTERT promoter,
which in turn attenuates a transcriptional activity of the hTERT
gene. Consistent with this hypothesis, we indeed observed that the
depletion of LSD1 led to not only increased H3-K4(M2) but also
H3-K4(M3) at the hTERT proximal promoter in HeLa cells (data
Figure 3. LSD1-depletion mediated up-regulation of hTERT and telomerase expression through enhancing H3-K4(M2) and H3 acetylation at the
hTERT proximal promoter in cancer cells. (A) The up-regulation of hTERT mRNA expression induced by depletion of LSD1 in human cancer cells. RT-
PCR for LSD1 mRNA was shown to verify efficient depletion of LSD1 expression in those cells. The lower panel further demonstrated an inhibition of
LSD1 expression at protein levels in HeLa and SiHa cells treated with LSD1 siRNA. WB: Western blot. (B) The enhanced telomerase activity in HeLa and
SiHa cells with LSD1 depletion. (C) The western blot analysis of global histone H3 acetylation, H3-K4, and H3-K9 mono-, di- and tri-methylation in
HeLa and SiHa cells transfected with LSD1 specific siRNA. Pansus staining was shown for equal histone protein loads. (D) The abolishment of LSD1
concomitant with the increased H3-K4(M2) and H3 acetylation at the hTERT proximal promoter in LSD1-depleted HeLa and SiHa cells. Representative
ChIP results were shown. C and L: Control and LSD1 siRNA, respectively.
doi:10.1371/journal.pone.0001446.g003
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cross-talk between LSD1 and deacetylating enzymes, and histone
demethylation can be a secondary target of HDAC inhibitors [40].
LSD1 interacts with CoREST which is in the HDAC-containing
complex [8,16], and thus it may further repress gene transcription
program via indirectly promoting histone deacetylation. Consis-
tently, we observed concomitant increases in histone H3-K4(M2)
and H3 acetylation in cervical cancer cells treated with either
LSD1 inhibitor or its specific siRNA. Taken together, LSD1 is
capable of regulating the chromatin structure of the hTERT
promoter region at multiple levels.
Although LSD1 was observed to occupy the hTERT proximal
promoter region, as demonstrated in our ChIP assay, it remains
unclear how it is recruited there. We examined a potential
interaction of LSD1 with the transcription factors Sp1 and MYC
family members, the key regulators for hTERT transcription, and
none of them were associated with LSD1 under our immunopre-
cipitation settings. It is thus plausible that LSD1 physically
associates with other co-factors that are in turn tethered to the
hTERT proximal promoter.
To conclude, the present study demonstrates that the histone
demethylase LSD1 is required for the transcriptional repression of
the hTERT gene in both normal and cancerous cells. By directly
demethylating H3-K4 and indirectly promoting H3 acetylation
associated with the hTERT core promoter, LSD1 participates in
the establishment of a stable repression state of the hTERT gene in
human normal or differentiated malignant cells. Our findings thus
provide insights into the regulatory mechanism underlying
telomerase silencing and activation in human cells, and have
implications in cancer and stem cell biology.
MATERIALS AND METHODS
Cell lines, culture conditions, and chemicals
Human cervical cancer cell lines HeLa, SiHa and SW756, lung
carcinoma cell line A549, normal fetal lung fibroblasts MRC5, and
leukemic cell line HL60 were cultured at 37uC/95%air/5%CO2 in
RPMI 1640 medium (Life Technologies, Paisley, Scotland, UK)
containing 10% fetal calf serum, 100 units/ml penicillin, and 2 mM
L-glutamine. The specific LSD1 inhibitor tranylcypromine and
histone deacetylase (HDAC) inhibitor trichostatin A (TSA) were
purchased from Biomol International LP (Plymouth Meeting, PA,
USA) and Sigma-Aldrich Sweden AB (Stockholm, Sweden),
respectively. HL60 cells were treated with 1.25% DMSO for
48 hours to induce their terminal differentiation [39].
siRNA treatment
ChemicalmodifiedStealth
TMsiRNAtargetingLSD1and CoREST,
and control siRNA were bought from Invitrogen (Carlsbad, CA,
USA). The sequences for LSD1 and CoREST were UUU CCA
UGA UAC CAG CAG CUU CUC C and AAG AUU GUC CCG
UUC UUG ACU GCG U, respectively. MRC5 and cervical cancer
cells were transfected with siRNA using Lipofectamine2000
(Invitrogen) according to the manufacturer’s protocol.
Total RNA extraction and RT-PCR
Total cellular RNA was extracted using ULTRASPEC
TM-II RNA
kit (Biotecx Lab, Houston, TX, USA). cDNA synthesis, the RT-
PCR primers and conditions for hTERT mRNA were as described
previously [46]. b2-M mRNA expression was used as a control for
RNA loading and RT efficiency and was amplified with its specific
primers for 26 cycles. PCR for both hTERT and b2-M mRNA
was optimised to keep amplification in a linear phase, which
allowed a semi-quantitative evaluation for the level of hTERT
transcript as described [46]. The PCR primers for LSD1 mRNA
are 59-GAC TTC TTG GCA GAG TTG TC-39 (forward) and 59-
GTG AAA GAG TTG CAG ATC C-39 (reverse). RT-PCR for
CoREST mRNA was carried out using the following primer pair:
(forward) 59-GGG ATG CTC TTC TGG CAT AA-39 and
(reverse) 59-GGA GGT TTC CTT TTT GCT CTA-39.
Histone and total cellular protein extraction, and
western blot
Preparation of a total histone fraction from nuclei was done by
extraction with a dilute acid as described [33]. Total cellular
proteins were extracted with RAIP lysis buffer. Two mg of histone
proteins or 20 mg of total cellular proteins were resolved by sodium
dodecyl sulate-polyacrylamide gel electrophoresis and transferred
to an intracellulos membrane. The membranes were probed with
the specific antibodies against methylated histone H3-K4(M1, M2
and M3), H3-K9(M1, M2 and M3), acetylated H3 or LSD1
(Upstate, NY, USA) followed by anti-mouse horseradish peroxi-
dase-conjugated IgG and developed with the enhanced chemilu-
minescent method (ECL, Amersham, UK).
Telomerase activity assay
TeloTAGGG Telomerase PCR ELISA (Roche Diagnostics
Scandinavia AB, Stockholm, Sweden) based on Telomeric
Repeats Amplification Protocol was used to determine telomerase
activity in all samples in duplicate according to manufacturer’s
instruction (40). One mg of protein from total cell lysates was added
into the reaction mixture and the generated telomere product was
PCR-amplified using 23 cycles. Four ml of products was used for
ELISA assay and the level of telomerase activity was arbitrarily
expressed as absorbance (OD450–OD690).
Luciferase activity assay
Transfection for luciferase activity assay was performed in 24-well
plates using Lipofectamine2000 (Invitrogen). The hTERT lucif-
Figure 4. The recruitment of LSD1 to the hTERT proximal promoter
concomitant with repression of hTERT transcription in the differen-
tiated HL60 cells. (A) The down-regulation of hTERT mRNA expression
in HL60 cells undergoing terminal differentiation induced by DMSO
treatment. (B) The presence of LSD1 concomitant with a loss of H3-
K4(M2) at the hTERT proximal promoter region in differentiated but not
undifferentiated HL60 cells. Control: Undifferentiated HL60 cells and
DMSO: DMSO-induced differentiated HL60 cells.
doi:10.1371/journal.pone.0001446.g004
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University, Japan), harbors the core promoter sequence of the
hTERT 59-flanking region [37]. p181 was co-transfected with a
Renilla reniformis luciferase-containing plasmid, which is under
control of the thymidine kinase (TK) promoter. The transfected
cells were then treated with different concentrations of tranylcy-
promine. Luciferase activity in the cell lysates was determined by
using a dual luciferase reporter assay system (Promega, WI, USA)
48 hrs post-transfection, and the hTERT promoter-driven firefly
luciferase activity was normalized to the TK renilla activity.
ChIP assay
ChIP assay was done as described [33,34]. The HeLa, SiHa and
HL60 cells, under different treatment conditions, were cross-linked
by incubating them in 1% (vol/vol) formaldehyde-containing
medium for 10 mins at 37uC and then sonicated to make soluble
chromatin with DNA fragments between 200 and 1000 bps. The
antibodies against LSD1, H3-K4(M2), H3-K9(M2), and acetylated
histone H3 (Upstate, NY, USA) were used to precipitate DNA
fragments bound by their corresponding elements. The protein-
DNA complex was collected with protein A or G Sepharose beads
(Upstate), eluted, and reverse cross-linked. Following treatment
with Protease K (Sigma), the samples were extracted with phenol-
chloroform and precipitated with ethanol. The recovered DNA
was re-suspended in TE buffer and used for the PCR amplification
as described [33,34]. The PCR primers for the proximal promoter
regions (spanning between –296 and –22 relative to ATG) were 59-
CCA GGC CGG GCT CCC AGT GGA T-39 (forward) and 59-
GGC TTC CCA CGT GCG CAG CAG GA-39 (reverse). The
primers for GAPDH were described elsewhere [33].
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